Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

The intriguing VEGFxPD-1 bispecific antibody space gained oomph with phase III results disclosed April 23 by Akeso Pharmaceuticals Inc. related to Harmoni-6, testing ivonescimab in combination with ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Researchers with City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention of both chemotherapy- and antibody-drug conjugate- (ADC) ...

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention of ...